Klaus Rabe, AAAAI 2021 – The Efficacy of Dupilumab in GINA-Defined Difficult To-Treat Type 2 Asthma Patients (Part 2)

Dr Klaus Rabe (Lung Clinic Großhansdorf and The University of Kiel, Germany) spoke with touchRESPIRATORY around his post-hoc analysis of the LIBERTY ASTHMA QUEST study (Clinical Trial Identifier: NCT02414854).

The abstract ‘Dupilumab Efficacy in GINA-Defined Difficult To-Treat Type 2 Asthma Patients in the LIBERTY ASTHMA QUEST Study.’ (ABSTRACT NUMBER: 183) was presented at the American Academy of Allergy, Asthma & Immunology Virtual Annual Meeting, February 26-March 1, 2021.

Questions

1. What were the aims and design of your post-hoc analysis of the LIBERTY ASTHMA QUEST study data? (0:06)
2. What were the findings of this analysis? (3:09)
3. What are the implications of these findings for future clinical practice? (3:52)

Disclosures: Klaus Rabe has nothing to disclose in relation to this video.

Support: Interview and filming supported by Touch Medical Media.

Filmed as a highlight of AAAAI 2021 (Virtual).